VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ANGO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ANGOAngioDynamics, Inc.
$13.07$540M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

ANGO logoAngioDynamics, Inc.(ANGO)Earnings, Financials & Key Ratios

ANGO•NASDAQ
$13.07
Price updated Jul 7, 2026
SectorHealthcareIndustryMedical InstrumentsSub-IndustrySurgical and interventional devices
AboutAngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.Show more
  • Revenue$292M-3.8%
  • EBITDA-$14M+91.4%
  • Net Income-$34M+81.6%
  • EPS (Diluted)-0.83+81.9%
  • Gross Margin53.92%+5.9%
  • EBITDA Margin-4.84%+91.1%
  • Operating Margin-13.66%+78.4%
  • Net Margin-11.62%+80.8%
  • ROE-17.5%+72.3%

ANGO Price & Volume

AngioDynamics, Inc. (ANGO) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operating Losses Cloud Strategic Oncology Pivot

Investment Thesis • Updated 2026Q3

VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Persistent Operating Losses

Key Thesis Takeaways

  • AngioDynamics is currently navigating a challenging transition toward high-margin oncology products, yet the company continues to struggle with structural operating losses and inconsistent revenue growth.
  • While the balance sheet remains liquid with a current ratio of 2.35, the persistent erosion of equity to an accumulated deficit of -$454.5M raises significant concerns regarding long-term capital viability.
  • Investors should monitor whether the company can achieve operating leverage, as SG&A expenses frequently exceed 45% of revenue, preventing a clear path to sustainable profitability.

Verdict Logic

the company has failed to achieve a positive operating margin in any period since 2024Q2, and the reliance on stock-based compensation, which reached $2.7M in 2026Q3, continues to dilute shareholders without delivering GAAP profitability.

ANGO Growth Metrics

AngioDynamics, Inc. (ANGO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-1.97%
5 Years2.06%
3 Years-2.57%
TTM10.73%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM24.17%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM25.74%

Return on Capital

10 Years-12.98%
5 Years-19.82%
3 Years-28.86%
Last Year-18.56%

ANGO Recent Earnings

AngioDynamics, Inc. (ANGO) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Apr 2, 2026
Metric
Actual
Est
EPS
$0.07+36.4%
$0.11
Rev
$78M+2.2%
$77M
Q1 2026
Jan 6, 2026
Metric
Actual
Est
EPS
$0.15-50.0%
$0.10
Rev
$79M+3.9%
$76M
Q4 2025
Oct 2, 2025
Metric
Actual
Est
EPS
$0.10+28.6%
$0.14
Rev
$76M-0.8%
$76M
Q3 2025
Jul 15, 2025
Metric
Actual
Est
EPS
$0.03+76.9%
$0.13
Rev
$80M+7.9%
$74M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 2, 2026
$0.07vs $0.11+36.4%
$78Mvs $77M+2.2%
Q1 2026Jan 6, 2026
$0.15vs $0.10-50.0%
$79Mvs $76M+3.9%
Q4 2025Oct 2, 2025
$0.10vs $0.14+28.6%
$76Mvs $76M-0.8%
Q3 2025Jul 15, 2025
$0.03vs $0.13+76.9%
$80Mvs $74M+7.9%
Based on last 12 quarters of dataView full earnings history →

Latest ANGO News

Recent stock market news and headlines for AngioDynamics, Inc. (ANGO)

Business Wire·Jun 30, 2026
AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the fourth quarter and full year of fiscal year 2026 before the market open on Tuesday, July 14, 2026. The Company's management will host a conference call at 8:00 am ET the same day to discuss the re.

Zacks Investment Research·Jun 23, 2026
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now

ANGO's NanoKnife growth, strong Med Tech momentum and solid Q3 results support holding the stock despite tariff and inflation pressures.

Zacks Investment Research·Jun 18, 2026
ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study

AngioDynamics' FDA IDE approval for RELIEF advances NanoKnife IRE study as a potential minimally invasive BPH treatment.

Business Wire·Jun 17, 2026
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-.

Peers Comparison

Key metrics vs top competitors for AngioDynamics, Inc. (ANGO)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ANGO logoANGOAngioDynamics, Inc.Current
$13.07$540.04M-15.75-3.76%-11.62%-17.5%—
NVCR logoNVCRNovoCure Limited
$17.72$2.02B-14.528.28%-25.66%-50.82%—
ATRC logoATRCAtriCure, Inc.
$32.80$1.66B-136.6714.88%-0.83%-0.95%—
MMSI logoMMSIMerit Medical Systems, Inc.
$72.14$4.3B33.8711.66%9.03%8.95%—
ITGR logoITGRInteger Holdings Corporation
$91.90$3.16B31.807.57%7.67%8.23%—
CNMD logoCNMDCONMED Corporation
$34.24$1.06B22.685.16%4%5.4%—

Compare ANGO vs Peers

AngioDynamics, Inc. (ANGO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVCR

Most directly comparable listed peer for ANGO.

Scale Benchmark

vs ABT

Larger-name benchmark to compare ANGO against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVCR, ATRC, MMSI, ITGR

ANGO SEC Filings & Documents

AngioDynamics, Inc. (ANGO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 23, 2026·SEC

Material company update

Apr 2, 2026·SEC

Material company update

Feb 3, 2026·SEC

10-K Annual Reports

3
FY 2025

Jul 18, 2025·SEC

FY 2024

Jul 25, 2024·SEC

FY 2023

Aug 3, 2023·SEC

10-Q Quarterly Reports

6
FY 2026

Apr 2, 2026·SEC

FY 2026

Jan 6, 2026·SEC

FY 2025

Oct 2, 2025·SEC

Get notified when ANGO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ANGO Frequently Asked Questions

AngioDynamics, Inc. (ANGO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is AngioDynamics, Inc.'s revenue?

AngioDynamics, Inc. (ANGO) reported $313.7M in revenue for fiscal year 2025. This represents a 916% increase from $30.9M in 2002.

How fast is AngioDynamics, Inc. growing?

AngioDynamics, Inc. (ANGO) saw revenue decline by 3.8% over the past year.

Is ANGO profitable?

AngioDynamics, Inc. (ANGO) reported a net loss of $31.4M for fiscal year 2025.

Dividend & Returns
What is ANGO's return on equity?

AngioDynamics, Inc. (ANGO) has a return on equity (ROE) of -17.5%. Negative ROE indicates the company is unprofitable.

What is AngioDynamics, Inc.'s free cash flow?

AngioDynamics, Inc. (ANGO) generated $1.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in ANGO back in 2002?

Total return calculator · dividends reinvested · 24+ years of data

See returns →